Abbott Laboratories (ABT) Non-Current Debt (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Non-Current Debt data on file, last reported at $29.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 132.71% year-over-year to $29.6 billion; the trailing twelve-month figure through Mar 2026 stood at $29.6 billion (up 132.71% YoY), and the FY2025 full-year result was $9.9 billion, down 21.62% from the prior year.
• Non-Current Debt climbed to $29.6 billion in Q1 2026, from $9.9 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $29.6 billion in Q1 2026 to a low of $9.9 billion in Q4 2025.
• A 5-year average of $14.6 billion and a median of $13.6 billion in 2023 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt slipped 21.62% in 2025 and soared 132.71% in 2026, its largest moves.
• Tracing ABT's Non-Current Debt over 5 years: stood at $14.5 billion in 2022, then retreated by 6.36% to $13.6 billion in 2023, then retreated by 7.16% to $12.6 billion in 2024, then slipped by 21.62% to $9.9 billion in 2025, then jumped by 199.49% to $29.6 billion in 2026.
• Business Quant data shows ABT's Non-Current Debt at $29.6 billion in Q1 2026, $9.9 billion in Q4 2025, and $11.6 billion in Q3 2025.